ORLANDO (EGMN) - The first-generation oral bisphosphonate sodium clodronate improves overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials.Among 278 men with metastatic disease starting or responding to long-term hormone therapy, the 8-year overall survival was 22% in those who received four tablets per day (2,080 mg) of sodium clodronate for 3 years or less but only 14% in those given a placebo. Median overall...